Tyra advances oral dabogratinib 60 mg for intermediate-risk NMIBC to Phase III
SURF302 initial results for oral dabogratinib 60 mg in intermediate-risk NMIBC report 79% ORR and 64% CR, with favorable safety, especially in single marker lesion patients, advancing to Phase III.
Initial results from the SURF302 study show oral dabogratinib at 60 mg delivered strong efficacy and favorable safety in intermediate-risk NMIBC, with a 79% ORR and 64% CR rate, especially in patients with a single marker lesion. The drug is presented as a less invasive alternative to current therapies.